Showing results (121-130 of 236) with videos related to

Sort By:
Pageof 24
Liver International : Official Journal of the International Association for the Study of the Liver|September 6, 2003
Sustained biochemical remission after interferon treatment may closely be related to the end of treatment biochemical response and associated with a lower incidence of hepatocarcinogenesisKenta Suzuki, Shogo Ohkoshi, Masahiko Yano, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|September 24, 2019
Pioglitazone, an agonist of PPARγ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expressionTakashi Higuchi, Norihiko Sugisawa, Kentaro Miyake, et al.
Digestive Diseases and Sciences|February 12, 2002
Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patientsMitsuhiro Takimoto, Shogo Ohkoshi, Takafumi Ichida, et al.
In Vivo (Athens, Greece)|April 28, 2025
HT1080 Human Fibrosarcoma Cells Selected for Super-eribulin Resistance In Vitro Become More Malignant and Are Arrested Synergistically by Methionine Restriction in Combination With Eribulin in Nude MiceSei Morinaga, Kohei Mizuta, Byung Mo Kang, et al.
Cancer Genomics & Proteomics|December 29, 2019
PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX ModelTakashi Higuchi, Jun Yamamoto, Norihiko Sugisawa, et al.
Cell Cycle (Georgetown, Tex.)|April 7, 2018
Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancerKei Kawaguchi, Kentaro Miyake, Qinghong Han, et al.
Frontiers in Oncology|December 24, 2025
Human fibrosarcoma cells selected for ultra-high doxorubicin resistance, acquire trabectedin cross-resistance, remain sensitive to recombinant methioninase, and have increased c-MYC expressionSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
In Vivo (Athens, Greece)|December 31, 2024
Synergistic Eradication of Fibrosarcoma With Acquired Ifosfamide Resistance Using Methionine Restriction Combined With Ifosfamide in Nude-mouse ModelsSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
In Vivo (Athens, Greece)|February 26, 2025
Dynamic Fluorescence Imaging of Orally-administered Tumor-targeting Salmonella typhimurium A1-R Expressing Green Fluorescent Protein Trafficking Through the Gastrointestinal System to Target Fibrosarcomas in Nude MiceSei Morinaga, Ming Zhao, Kohei Mizuta, et al.
Cancer Diagnosis & Prognosis|January 6, 2025
Elevated-c-MYC-expressing Fibrosarcoma Cells With Acquired Gemcitabine Resistance Remain Sensitive to Recombinant Methioninase: A Potential Clinical Strategy for a Recalcitrant DiseaseSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Pageof 24